The Novel 18F-labeled MAO-B PET Tracer Study in Parkinsonism Patients

Last updated: August 17, 2023
Sponsor: Anhui Provincial Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Dyskinesias

Treatment

18F-SMBT-1

Clinical Study ID

NCT06010290
MAO-B PET/CT STUDY
  • Ages 40-90
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

This study mainly aims to prospectively evaluate the changes of reactive astrogliosis in Parkinsonism patients of Chinese population by the novel 18F-labeled MAO-B PET tracer.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Aged from 40 to 90 years old.
  • Clinically diagnosed as Parkinsonism, including Parkinson's disease and atypicalParkinsonism syndromes.
  • Can cooperate with 18F-FDG PET/CT, 18F-FP-CIT PET/CT and 3D T1-weighted structural MRscans.
  • Complete clinical data, including modified Hoehn and Yahr staging scale and theMovement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS).

Exclusion

Exclusion Criteria:

  • Cannot cooperate with PET/CT or MR examination.
  • Associated with brain diseases such as stroke, brain trauma, brain tumor, and cranialsurgery.

Study Design

Total Participants: 80
Treatment Group(s): 1
Primary Treatment: 18F-SMBT-1
Phase:
Study Start date:
November 30, 2022
Estimated Completion Date:
December 31, 2023

Study Description

18F-SMBT-1, the novel 18F-labeled MAO-B PET tracer, was evaluated reactive astrogliosis in Alzheimer's disease successfully. In this prospective study, we assess the changes of reactive astrocytes in cerebral gray matter and white matter on Parkinson's disease by 18F-SMBT-1 PET/CT imaging among Chinese population.

Connect with a study center

  • The First Affiliated Hospital of China University of Science and Technology

    Hefei, Anhui 230000
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.